Safety, Tolerability and Efficacy of Uproleselan (GMI-1271) in Patients With COVID-19 Pneumonia

    Not Recruiting
  • days left to enroll
  • participants needed
  • sponsor
    Lena Napolitano, MD
Updated on 29 July 2023


The purpose of this study is to find out whether the drug uproleselan can help patients with severe COVID-19 pneumonia. Investigators will study both the side effects of the drug and assess if the drug will help patients recover more quickly and slow down the progression of acute respiratory failure.


Soluble E-selectin is a significant biomarker for ARDS. Soluble E-selectin also has pro-inflammatory properties further releasing cytokines and promoting its synthesis and the continued influx of neutrophils. Small molecule glycomimetic antagonists of E-selectin (rivipansel and uproleselan) are 500- to 1000-fold more potent inhibitors of E-selectin and have shown activity and no measurable toxicity in human clinical trials for other indications. Treatment with these E-selectin inhibitors reduced the levels of soluble E-selectin in the bloodstream which occurs during recovery of ARDS. Thus antagonists of E-selectin which include glycomimetic antagonists and more specifically, rivipansel (GMI-1070) and uproleselan (GMI-1271), may be used to treat COVID-19 patients with respiratory symptoms that may lead to ARDS

Primary Objective:

Safety of uproleselan in patients with severe COVID-19 pneumonia.

Secondary Objectives:

To evaluate if treatment with uproleselan administered intravenously in addition to the best available therapy according to institutional guidelines is able to reduce the progression of acute respiratory failure, in patients with severe COVID-19 pneumonia.

  • To evaluate proportion of patients alive and free of respiratory failure through Day 28
  • To evaluate overall survival and all-cause mortality at day 15 and 28.
  • To evaluate changes in the COVID ordinal outcomes scale.
  • To assess adverse events to evaluate the safety of uproleselan.
  • To assess ventilator-free days, ICU-free days, oxygen, vasopressor free days.
  • To evaluate changes in D-dimer.

Exploratory Objectives:

  • To examine the correlation of plasma soluble E-selectin concentrations with clinical outcomes.
  • To examine the correlations of other biomarkers of interest with clinical outcome.

Condition COVID-19 Pneumonia
Treatment Uproleselan
Clinical Study IdentifierNCT05057221
SponsorLena Napolitano, MD
Last Modified on29 July 2023

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note